Stock Movers Novo Nordisk's Pill, Orsted Winded, Pets At Home Up
Dec 23, 2025
Louise Moon, a Bloomberg reporter specializing in market analysis, discusses significant market shifts. Novo Nordisk has secured US approval for a pill version of its weight-loss drug Wegovy, a strategic move against Eli Lilly. Orsted is facing challenges with the suspension of leases for five offshore wind farms, considering legal action amidst potential losses. Finally, Pets at Home has appointed James Bailey to revive its fortunes, aiming for a turnaround by 2026.
AI Snips
Chapters
Transcript
Episode notes
Pill Approval Could Reset Obesity Drug Race
- Novo Nordisk won US approval to sell a pill version of Wegovy starting in January at $149 a month.
- The pill aims to help Novo regain ground lost to Eli Lilly and could expand globally if approved elsewhere.
Pill Tradeoff: Slightly Less Loss, Easier Use
- The pill reportedly produces about a 16% average body-weight drop, slightly less than injections.
- Its ease of ongoing use may make it a competitive alternative to shots for many patients.
US Lease Suspensions Threaten Offshore Wind Deals
- The US suspended leases for five East Coast offshore wind farms citing national security, risking about $28 billion in committed capital.
- Orsted and other European suppliers like Vestas face renewed regulatory and stock-price pressure from the decision.